A Case Report of Delusions in a Patient Receiving Cabergoline Therapy for Prolactinoma: Pathophysiology and Proposed Treatment With Aripiprazole

Cabergoline is a dopamine 2 receptor agonist used as first-line treatment of pituitary prolactinomas. Here, we describe the case of a 32-year-old woman with a pituitary prolactinoma who was treated with cabergoline for 1 year, during which time she developed delusions. We also discuss the use of ari...

Full description

Saved in:
Bibliographic Details
Published inClinical neuropharmacology Vol. 46; no. 3; p. 126
Main Authors Springer, Charles, Rodgers, Robert, Vivino, Gina, Attanagoda, Saritha, Miks, Charles Dylan
Format Journal Article
LanguageEnglish
Published United States 01.05.2023
Subjects
Adult
Aripiprazole - adverse effects
Cabergoline
Delusions
Dopamine Agonists - adverse effects
Ergolines - adverse effects
Female
Humans
Pituitary Neoplasms - drug therapy
Prolactinoma - drug therapy
Online AccessGet more information

Cover

More Information
Summary:Cabergoline is a dopamine 2 receptor agonist used as first-line treatment of pituitary prolactinomas. Here, we describe the case of a 32-year-old woman with a pituitary prolactinoma who was treated with cabergoline for 1 year, during which time she developed delusions. We also discuss the use of aripiprazole to mitigate the psychotic symptoms, while maintaining the efficacy of cabergoline treatment.
ISSN:1537-162X
DOI:10.1097/WNF.0000000000000547